Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A2 | O43868 | 4/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ADK | P55263 | 1/20 | 0.30 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6039053 | 0.84 | TYMP (0.44) | SLC28A2GSK3BCDK5CDK5R1TYMP | |
| SCHEMBL15954506 | 0.79 | TYMP (0.40) | TYMPADORA2AADORA2BADORA3 | |
| SCHEMBL7534659 | 0.78 | KDM4E (0.49) | TYMPALDH1A1 | |
| SCHEMBL2113125 | 0.78 | KDM4E (0.49) | TYMPALDH1A1 | |
| SCHEMBL2113460 | 0.76 | POLB (0.41) | TYMPALDH1A1ADORA3 | |
| SCHEMBL7596995 | 0.75 | ADORA1 (0.36) | ADORA2AADORA2BADORA3 | |
| SCHEMBL888001 | 0.74 | ADORA3 (0.45) | ADORA2AADORA2BADORA3 | |
| SCHEMBL1499972 | 0.72 | ADORA1 (0.47) | TYMP | |
| SCHEMBL14556178 | 0.72 | TYMP (0.39) | TYMPADORA2AADORA2BADORA3 | |
| SCHEMBL2112347 | 0.72 | ADORA3 (0.47) | ADORA2AADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060008813-A1 | Compositions and methods of synthesis and use of novel nucleic acid structures | ERITJA RAMON | 2006-01-12 | — | — | US | disclosed |
| US-6831072-B2 | Such as 8-amino-2'deoxyadenosine by treating 8-azido-2'deoxyadenosine with aqueous solution of methylamine or dimethylamine; for targeting nucleic acids without amplification and less use of enzymes | CYGENE, INC. | 2004-12-14 | — | — | US | disclosed |
| US-20030135040-A1 | Compositions and methods of synthesis and use of novel nucleic acid structures | CYGENE, INC. | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135040-A1 | Compositions and methods of synthesis and use of novel nucleic acid structures | ADAR, NSUN2, RNGTT | SLC28A2 222/4885GSK3B 4509/4885CDK5 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.